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Abstract The isolation of five new mouse estrogen receptor K
mRNA variants (mERK A, B, F1, F2 and H) is described. All of
these transcripts are generated by alternative splicing and all
encode the 66 kDa ERK protein that the previously identified
mRNA C variant generates. However, these transcripts differ in
their 5P untranslated regions. RT-PCR and S1 nuclease
protection assays revealed a tissue- and sex-specific expression
pattern of all variants. The C and F mRNA variants are the
predominantly expressed mERK variants in mouse. The expres-
sion of mERK H mRNA is restricted to liver, although female
mice produce around a five fold higher level of this transcript
than males. Our results show that the mERK gene is a complex
genomic unit in mice that exhibits alternative splicing which is
regulated in a tissue-specific manner. ß 2000 Federation of
European Biochemical Societies. Published by Elsevier Science
B.V. All rights reserved.
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1. Introduction
Estrogens play a pivotal role in sexual development and in
reproduction [1], as well as in physiological processes in var-
ious tissues such as mammary gland, pituitary, bone, liver and
the cardio-vascular system. Estrogens are also involved in
various pathological processes such as breast and endometrial
cancer [2] and osteoporosis [3]. The physiological e¡ects re-
sulting from estrogen action on target tissues often induce
changes in the expression patterns of speci¢c target genes.
These are mediated by intracellular receptors, which bind es-
trogen [4,5]. To date, two nuclear estrogen receptors ERK-
NR3A1 and ERL-NR3A2 (Nuclear Receptors Nomenclature
Committee, 1999 [33]) have been identi¢ed [6,7]. Both recep-
tors belong to the superfamily of nuclear receptors and steroid
receptors family that act as ligand-inducible transcription fac-
tors [8^10]. These factors share a common overall structure,
consisting of six domains (A^F) as demonstrated by homol-
ogy comparison [11,12]. Two transactivation functions,
known as AF-1 and AF-2 are located in the A/B and E do-
mains, respectively. Domain C mediates binding to target
DNA through a zinc ¢nger motif. Domain D has a nuclear
localisation signal and domain E interacts with ligand, thereby
conferring ligand dependency on the AF-2 domain. Finally
Domain F has been shown to modulate the magnitude of
target gene activation [13].
ERK and ERL are expressed in various cell types and tis-
sues and the expression levels of their respective mRNAs ap-
pear to be regulated in a tissue-speci¢c and temporal manner.
Furthermore, the ER mRNA levels are in£uenced by estrogen
itself [14^16] or by other hormones [17^19]. A more complete
understanding of the mechanism(s) that regulate(s) the tissue-
speci¢c and temporal expression of ERs is essential towards
understanding how the pleiotropic e¡ects of estrogens are
achieved in complex organisms.
During the late 1980s the cDNAs encoding human [6],
chicken [11], mouse [20] and rat [21] ERK were cloned. Sur-
prisingly, the ¢rst exon of mouse and rat had low homology
to the human ¢rst exon [20,21]. However, the discovery of a
second promoter and exon located approximately 1.9 kbp up-
stream of the initially reported transcription start site [6] in
the human estrogen receptor gene [22,23] showed high homol-
ogy to the ¢rst exon of the previously described mouse estro-
gen receptor K (mERK) gene [20]. Subsequently, other up-
stream exons in the ERK gene of human [24] and rat [25,26]
were identi¢ed. Additionally, we have recently shown that the
estrogen receptor K gene is transcribed from at least four
promoters in chicken and from six promoters in human
[27,28].
Although the mouse is extensively used as a model organ-
ism to study ERK regulation in vivo, the complete structure of
the mERK gene has not, to date, been elucidated. Thus, the
aim of this study has been to investigate if multiple mERK
mRNA variants are expressed in mouse as has been described
in humans and in chickens. Using the rapid ampli¢cation of
cDNA ends (RACE) and RT-PCR techniques we have iden-
ti¢ed ¢ve novel mRNA variants generated by the mERK.
These transcripts are generated in a tissue-speci¢c manner
by di¡erential promoter usage and through alternative splic-
ing of upstream exons. Moreover, sequence alignment of the
new upstream exons showed high homology to human and rat
ERK genes. This study indicates that the estrogen receptor
gene K is a complex transcription unit with tissue-speci¢c
promoter usage and alternative splicing that has been con-
served between various species during evolution.
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2. Materials and methods
2.1. Note to the terminology used in this study
All upstream untranslated exons are named with a single capital
letter starting with the letter ’A’. All exons and mRNA variants ho-
mologous to human ERK (A, B, C, F) bear a name based on that
given in Flouriot et al. [28]. The mRNA originally cloned by White et
al. [20] is termed ’C’. Letters D and E were skipped due to the exis-
tence of such upstream exons in human and/or chicken ERK gene and
which are not homologous to any described mouse ERK exon. Coding
exons are simply numbered from exon 1 (containing the translation
initiation ATG) to exon 8.
All position numbers are according to the sequence of cDNA
cloned by White et al. [20].
2.2. RACE
A modi¢ed RACE technique was used to amplify the 5P ends of
mERK mRNA variants. In essence, a long, highly labelled primer,
complementary to the 252 nt region downstream of the initiating
AUG from position +191 to +443 of mERK mRNA was prepared
using a biotinylated template as described [29]. Total RNA (35 Wg)
from uterus and from liver were co-precipitated with the primer, re-
suspended in hybridisation bu¡er and hybridised overnight at 55‡C.
The primed RNA was precipitated and reverse-transcribed at 42‡C
using 50 U of Expand1 reverse transcriptase (Roche Diagnostics,
Mannheim, Germany) following the instructions of the manufacturer.
RNA in RNA/DNA hybrids was then degraded using DNase-
free pancreatic RNAse. One half was then loaded on a denaturing
polyacrylamide gel to check the primer extension pattern. The second
half was tailed with dCTP using terminal deoxy transferase (Gibco-
BRL, Eggenstein, Germany) as described by the manufacturer. Tailed
cDNA was then ampli¢ed by PCR using upstream anchor prim-
er (5P-GGCCACGCGTCGACTAGTACGGGIIGGGIIGGGIIG-3P)
and downstream primers P1 (5P-GGCAGCCGGCGAGTTACAGA-
3P) and P2 (5P-GCTCCCCGCGCACGCAGAGG-3P) located in exon
1. PCR products were subcloned in the TA cloning vector pCR12.1
(Invitrogen, San Diego, CA, USA) and colonies were screened with
oligonucleotides C1 (5P-ATCACACACCGCGCCACTCGATCAT-
3P), speci¢c for the C mRNA variant [20] and P3 (5P-CTCAGCA-
GCGCGTGGGCCAC-3P) which is nested to primer P2. Clones that
hybridised with the P3 probe but not with the C1 probe were se-
quenced.
2.3. RNA isolation
Adult female or male mice were killed by cervical dislocation. The
uterus, brain, lung, kidney, femoral muscle, aorta, liver and testis were
immediately removed and frozen in liquid nitrogen. Tissues were
stored at 380‡C before use. Total RNA was extracted from tissues
of several mice using TRIzol reagent (Gibco-BRL, Eggenstein, Ger-
many) as described by the manufacturer. RNA was dissolved in water,
aliquoted and stored in 380‡C. A quality of the RNA was checked by
agarose gel electrophoresis. The ratio of absorbance at 260 and 280 nm
was in the range between 1.8 and 1.9. The complete coding region of
the estrogen receptor K cDNA (2010 bp) was consistently ampli¢ed
from the isolated RNA, which was used for all experiments.
2.4. RT-PCR
Total RNA (2 Wg) was reverse transcribed using Expand1 reverse
transcriptase (Roche diagnostics) as described by the manufacturer
with a primer 5P-ATGAACCAGCTCCCTATCTG-3P, which is com-
plementary to exon 4 of the mERK gene. 10% of the resulting cDNA
was used as a template in two rounds of PCR using nested upstream
primers speci¢c for di¡erent 5Pends of mRNA variants and down-
stream primers speci¢c for exon 4 (5P-TTCAACATTCTCCCT-
CCTCGGCGGTCTTTC-3P and exon 3 (5P-TTCATCATGCCCACT-
TCGTAACACT-3P). Sequences of nested PCR primers speci¢c for
various 5PUTRs were as follows: Exon A: 5P-AACTATGCGTG-
CGCCTTCTCTAAT-3P, 5P-CTTCTCTAATCGCAGGCTCTACTC-
T-3P. Exon B: 5P-TCCACCCCTGCAGCGAATCC-3P, 5-CAGCGA-
ATCCAGCAGCGAAGACC-3P. Exon C: 5P-ATCACACACCGC-
GCCACTCGATCAT-3P, 5-ATTCCTTCCTTCCGTCTTACTGTCT-
CA-3P. Exon F1: 5P-TGCCCCCTCCTCTGCCATTGTCT-3P, 5P-
TCTCTGGGCGACATTCTTCTCAA-3P. The primer complementary
to the rat 0S mRNA variant [26] used for isolating and cloning of the
mouse F mRNA variant was 5P-GAAAACACAAGGCTCCATGCT-
3P. Ampli¢ed products were separated by agarose gel electrophoresis
and transferred to Hybond N+ membrane (Amersham) with a Semi-
Dry Electrotransfer unit (Bio-Rad). Membranes were hybridised
under stringent conditions with 32P end-labelled oligonucleotide
probes speci¢c for exons 1, 2 or 3 of the mERK gene.
2.5. Sequence analysis and alignment
All sequence alignments were computer-assisted using the Gap pair-
wise comparison procedure in Wisconsin Package Version 10.0, Ge-
netics Computer Group (GCG), Madison, WI, USA.
2.6. S1 nuclease assay
A modi¢ed S1 nuclease protection assay was performed as de-
scribed [30]. As probe templates fragments obtained in RACE or
RT-PCR experiments cloned into the TA cloning vector pCRTM2.1
(Invitrogen, San Diego, CA, USA) were used. The probe templates
were ampli¢ed from the vector using either biotinylated M13 or M13
reverse primers. Biotinylated PCR products were bound to strepta-
vidin-coated magnetic beads (Dynal, Great Neck, NY, USA) as rec-
ommended by the manufacturer and the non-biotinylated DNA
strands were eluted with 0.2 M NaOH. A primer complementary to
the 3P end of the exon one (5P-GTAGAAGGCGGGAGGGCCG-
GTGTCGCGCA-3P) was then annealed to the single-stranded DNA
and extended using T7 DNA polymerase in presence of [K32-P]dCTP
(3000 Ci/mmol). Thus the resulting probes were complementary to the
whole exon 1 and the complete isolated 5PUTR speci¢c sequences.
Extended products were denatured with 0.2 N NaOH and puri¢ed
on an 8% denaturing polyacrylamide^urea gel. This probe (104 cpm)
was co-precipitated with 30 Wg of total RNA and then dissolved in
20 Wl hybridisation bu¡er. Samples were denatured at 70‡C for 10 min
and hybridised overnight at 55‡C. S1 digestions were then carried out
in the presence of 300 units of S1 nuclease for 1 h at 30‡C and after
precipitation, the samples were separated on 4% polyacrylamide^urea
gels and exposed to ¢lm.
3. Results
3.1. Multiple mRNA variants of the mERK
Sequence alignment of mouse ERK mRNA [20] with vari-
ous human and chicken ERK mRNA variants predicted that a
conserved common acceptor splice site exists at position +119
in exon 1 of the mouse ERK gene. In order to investigate if
more than one mERK mRNA variant occurs in mouse by
alternative splicing of upstream exons to the splice acceptor
site at +119, S1 nuclease protection assay was performed us-
ing a probe spanning the region +1 to +652 of the original
mERK mRNA described by White et al. [20] (renamed as
variant C in this study), with total mRNA from several mouse
tissues. Two protected fragments were observed in all tissues;
one corresponding to mERK mRNA variant C (totally pro-
tected probe) and another shorter fragment corresponding in
size to the cDNA from position +119 to +652 (Fig. 1). The
presence of a strong signal for the shorter protected fragment
in all tissues tested indicated an existence of unknown mERK
mRNA variant(s) in addition to the mERK C mRNA variant.
A similar experiment with equivalent results was performed
with a longer S1 probe spanning the region +1 to +1270 (data
not shown).
In order to isolate further 5P end(s) of unknown mERK
mRNA variant(s) a modi¢ed technique of RACE was per-
formed. A long, highly radioactive labelled primer spanning
the region of 252 nucleotides downstream of the initiator
ATG in the ¢rst exon of the mouse ERK gene was used. In
addition to the previously described variant C, the 5Pends of
three di¡erent mERK mRNA variants (A, F, H) were cloned
from uterus and liver total RNA isolated from adult female
mouse. Variant A corresponds to the genomic sequence that is
directly upstream of the ¢rst coding exon of mERK gene. A
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homologous human ERK mRNA was the ¢rst ERK mRNA
cloned [6] (Fig. 2). Part of the sequence of the mERK H
mRNA variant was almost identical to the rat ERK mRNA
variant isolated from liver [31] but extended further in 5P
direction (Fig. 2). Although only six nucleotides of mRNA
variant F were isolated, it was present in 20% of clones gen-
erated by RACE.
The murine mRNA variant A isolated in RACE experi-
ments showed homology to the human ERK A mRNA var-
iant, which is transcribed from a promoter located upstream
of the ¢rst translated exon of human ERK gene. As another
human mRNA variant (B) is transcribed from the promoter
located upstream of promoter A [28], we were interested if an
analogous promoter exists in mouse. The intronic region,
spanning approximately 2 kbp between the originally de-
scribed ¢rst exon and the ¢rst translated exon of the mouse
ERK gene, was cloned and sequenced. Alignment with the
corresponding promoter region of the human ERK gene re-
vealed homology to the A and B promoters and associated
exons of the hERK gene [28]. This suggested that promoter B
might also be functional in mouse. RT-PCR with mRNA
from uterus and liver using primers complementary to this
B homologous region and downstream primers located in
the translated exon 2 con¢rmed the expression of this
mERK B mRNA variant in these two tissues (data not
shown). Additionally, a PCR product longer than expected
was ampli¢ed with primers speci¢c for exon B. Sequencing
analysis revealed an mRNA variant generated by utilisation
of another donor splice site located 100 bp downstream of the
donor splice site in exon B that is conserved between human
and mouse. This longer variant was called B2.
As two mouse ERK mRNA variants (C and H) showed
high homology to rat sequences (Fig. 2) we decided to inves-
tigate if the other two known rat ERK mRNA variants 0N
and 0S [25,26] have counterparts in mouse. RT-PCR analysis
of total RNA from mouse uterus and liver using upstream
primers complementary to the sequences of rat 0N and 0S
ERK mRNA variants [25,26] con¢rmed the presence of a cor-
responding ERK 0S mRNA variant [26] in mouse. However,
the rat ERK 0N mRNA variant [25] was not detected in these
tissues, which might be due to the low homology of the used
rat 0N primers to the mouse sequences. Unexpectedly, two
Fig. 1. Scheme of mERK gene and mRNA as described by White et al. [20] with the potential upstream untranslated exon represented by a
dark grey rectangle with ’?’ and the dashed line representing splicing to a common acceptor splice site located in the ¢rst translated exon. The
translation initiation AUG is depicted. S1 nuclease assay probe spanning the region of mERK mRNA from the transcription start site up to
the end of exon 1 and including non-homologous vector sequence at its 3P end and presumed protected fragments are outlined below. On the
right the autoradiogram of the experiment is shown.
Fig. 2. Presentation of the alignment of the 5P region of the human, mouse and rat estrogen receptor K genes. Various upstream untranslated
exons (A^H) are depicted as boxes. EMBL nucleotide sequence database accession numbers or other sources of the sequences used are shown
(new sequences in bold type). Numbers within the boxes represent the percentage of identity between mouse and human or mouse and rat se-
quences respectively. The question mark (’?’) is used where no sequence data are available. Observed splicing of mouse ERK upstream exons is
depicted as thin lines.
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products were ampli¢ed with primers complementary to the
rat 0S mRNA variant. Sequence analysis of both fragments
revealed a sequence highly homologous to the rat ERK
mRNA variant 0S [26] but with a sequence inserted between
the common splice site and the region homologous to 0S in
the longer fragment. This 109 bp sequence, as well as the
corresponding part of the longer sequence, is highly homolo-
gous to the recently described hERK F mRNA variant [28]
and therefore we termed these two new sequences F1 (shorter
sequence) and F2 (109 bp inserted sequence)(Fig. 2). Align-
ment with a contig (EMBL: AL035695) from the human
chromosome 6, where the human ERK gene is localised, re-
vealed that regions homologous to F1 and F2 are located
approximately 60 kbp apart in the human genome and there-
fore are two separate exons. In mouse, exon F1 is either
spliced directly to the common acceptor splice site or to
exon F2 and then to the common acceptor splice site +119
(Fig. 2). Furthermore, the six nucleotides isolated in the
RACE experiment are derived from exon F2 and are present
upstream of the donor splice site. It is not clear if this is an
artefact of RACE, as RT-PCR analysis consistently ampli¢ed
the entire F2 region. As the F2 exon is part of the F1F2
mRNA variant the F2 mRNA variant cannot be distinguished
by PCR using an F2 speci¢c primer. Thus experiments were
performed using the F1 speci¢c primers and S1 probes com-
plementary to the F1F2 mRNA variant. For simplicity we
refer to this longer variant in the following text as ’F’.
Alignment of various upstream exons of mouse ERK
gene with their equivalents from human and rat and the pro-
posed genomic organisation of the 5P region is presented in
Fig. 2.
3.2. Tissue-speci¢c expression of mERK mRNA variants
RT-PCR analysis was used to determine if ER-K mRNA
variants are di¡erentially expressed in various mouse tissues.
Variants A, C and F were detected in all tissues tested. How-
ever, mRNA variant B was not detected in lung and aorta and
mRNA variant H was present only in liver and testis. The
Fig. 3. S1 nuclease protection assay using probes complementary to the ¢ve new mERK mRNA variants. Top: a generalised diagram of an
mRNA variant, the region covered by the probe and expected protected fragments is shown. Autoradiograms of S1 nuclease protection assay
with probes complementary to mERK mRNA variants A, B, F and H are shown.
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expression pro¢les of the various mRNA variants in particu-
lar tissues are summarised in Table 1.
As RT-PCR does not provide a quantitative determination
of transcripts in cells, S1 nuclease protection assays were used
to estimate the relative abundance of mERK mRNAs in a
panel of mouse tissues (Fig. 3). The probes used contained
the speci¢c part of the particular mRNA variant followed by
a sequence complementary to exon 1 and short vector se-
quence at the 5P end to distinguish digested from undigested
probe (see Fig. 3). Hence two protected fragments were an-
ticipated, a fragment corresponding to fully protected probe,
i.e. corresponding to the particular mERK mRNA variant,
and a second shorter protected fragment corresponding to
exon 1, which is common to all mRNA variants. This allows
an estimation of the relative abundance of the particular
mRNA variants in tissues by comparing the signal intensities
for those two fragments. Variants A and B were not detect-
able by S1 nuclease protection assay indicating that their lev-
els of expression in the tissues tested are very low. Variant C
was expressed in all tissues examined and was the major
mRNA variant present in uterus, brain, and skeletal muscle.
Also, the mRNA variant F was detected in all tissues eval-
uated except brain and represents the predominant mRNA
variant in liver. The H mERK mRNA variant was also de-
tected by S1 nuclease protection assay only in male and fe-
male liver. Results of quanti¢cation using densitometric anal-
ysis together with RT-PCR analysis are summarised in Table
1.
4. Discussion
This study indicates that the mERK gene is transcribed
from at least ¢ve di¡erent promoters. Even though the exis-
tence of several promoters of human, chicken and rat ERK
genes has already been demonstrated [22,24,27,28], the se-
quences of mouse upstream exons have remained unknown
so far. Various mRNA splice variants within the coding re-
gion of mouse ERK were reported [32]. However, no informa-
tion on the organisation of the 5P region of the mERK gene
has been available to date. Sequence alignment of newly de-
scribed exons indicates a high degree of homology between
human, rat and mouse 5P UTRs. Various promoter utilisation
and alternative splicing generate mRNA variants that di¡er in
their 5P untranslated regions. All these mRNAs can be trans-
lated into the same 66 kDa ERK protein. The presence of
multiple promoters seems to be a general feature of steroid/
thyroid hormone/retinoic acid receptors. Each cell type pos-
sesses a di¡erent composition of transcription factors, cofac-
tors and other regulatory proteins that selectively direct uti-
lisation of various promoters. Presumably multiple promoters
are used to achieve various levels of expression of mERK
protein needed for the particular cell function.
S1 analysis of several mouse tissues revealed a tissue speci¢c
expression for all mRNA variants. The abundance of mRNA
variants is very di¡erent in all tissues tested. Surprisingly,
although the mRNA A variant is highly expressed in several
human tissues and in breast cancer cell lines [28], in mouse
tissues it was detected only by RT-PCR and not by S1 nucle-
ase protection assay. Though the sequence alignment of
mouse and human promoter A region show high homology,
recognition sequences required for utilisation of this promoter
may have been lost during evolution of the mouse. Variant B
is expressed in the tissues tested at levels not detectable by S1
nuclease protection assay and it is also not a major mRNA
variant in human [28]. Murine variant H it is almost identical
to the rat ERK mRNA variant isolated from liver by Frey-
schuss and Grandien [31]. As demonstrated in this study by
S1 analysis, use of this promoter is restricted to liver in
mouse. The expression pro¢le of this variant in rat has not
been reported. The level of expression of variant H is di¡erent
between the two sexes as in female liver it forms almost one
third of total mERK mRNA while in the male liver it is a
minor mERK mRNA variant. Interestingly, variant H is not
homologous to the human mRNA variant E [28], which was
also detected exclusively in human liver by S1 nuclease pro-
tection assay. Presumably, the H promoter is responsive only
to transcription factors that are expressed only in this tissue.
Variants C and F are expressed in all tissues tested (in both
mouse and human) and are the major mRNA variants present
in mouse. Variant C is highly expressed in uterus, testis, brain,
skeletal muscle and aorta, where it is the major mERK mRNA
variant. Unlike the mERK C, variant F is predominant in
liver of both sexes. Interestingly, the ratio of variants C and
F in uterus and testis are similar. Both are reproductive tissues
and might possess a similar array of transcription factors and
other cofactors that can activate this promoter. Variants C
and F may generate a basal level of ERK protein that is
required for the physiological functions of cells and a tempo-
ral requirement of higher ERK levels can be regulated by
switching on other promoters in a particular tissue.
The estimation of the relative abundance of mRNA var-
iants shows that the sum of the relative amounts of variants
A, B, C, F and H does not account for the strong signal
obtained for protected exon 1 fragment in S1 analysis in all
tissues except uterus and female liver. It is therefore likely that
other unknown upstream exons or other alternatively spliced
mRNA variants exist in other tissues. The fact that they were
not detected by RACE suggests that these putative mRNA
variants are expressed at very low levels in uterus and in liver,
which were used as a source of mRNA for RACE. The total
levels of mERK expression di¡er between tissues. ERK is
highly expressed in uterus and liver and to a lower extent in
Table 1
RT-PCR and S1 analysis of the tissue distribution of mRNA var-
iants
Tissue/variant A B C F H Total
Uterus + + 53 28 3 81
Brain + + 49 + 3 49
Lung + 3 9 26 3 35
Kidney + + 6 27 3 33
Skeletal muscle + + 60 16 3 76
Aorta + 3 40 12 3 52
Liver female + + 7 49 28 84
Liver male + + 13 41 6 60
Testis + + 32 16 + 48
Presence or absence of mERK mRNA variants in various tissues as
observed in RT-PCR and S1 nuclease protection experiments: 3
mRNA variant observed neither in RT-PCR nor S1 analysis; +
mRNA variant detected by RT-PCR only; Number stand for the
relative abundance (in percent) of a particular mRNA variant in a
tissue as estimated from S1 nuclease protection assay experiments
(quanti¢cation: speci¢c protected fragment+common protected frag-
ment = 100%).
In the column ’total’ the sum of the relative abundance of all
mRNA variants in a tissue is calculated.
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skeletal muscle and aorta. However in other tissues mERK
expression is hardly detectable by S1 nuclease protection as-
say.
In this study ¢ve new mERK mRNA variants and a likely
genomic organisation of the 5P region of the mERK gene are
presented. Mice are often used as a model to study the role of
estrogens in mammals. The sequences of the new upstream
exons presented and their adjacent regions contribute to the
understanding of the mechanisms of estrogen action in vari-
ous physiological and pathological conditions.
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